Results 111 to 120 of about 13,471,027 (144)

N-Acetylprocainamide's Antiarrhythmic Action in Patients with Ventricular Tachycardia

Angiology, 1986
Antiarrhythmic properties of N-acetylprocainamide, an active metabolite of procainamide, were studied in 15 patients who presented with a cardiac arrest or documented sustained ventricular tachycardia. Programmed electrical stimulation studies were performed. All patients tested had inducible ventricular tachycardia by programmed electrical stimulation
J, Somberg, J, Wynn, D, Miura, V, Torres, S, Williams, D, Keefe   +5 more
openaire   +2 more sources

The quantitative disposition of procainamide and N-acetylprocainamide in the rat.

The Journal of Pharmacology and Experimental Therapeutics, 1978
The objectives of this study were to investigate: 1) the rat acetylator phenotype, 2) the systemic availability of oral procainamide (PA), 3) the kinetic disposition of PA and its N-acetyl metabolite (NAPA) and 4) the relationship between PA dose and steady-state blood PA and NAPA levels.
D W, Schneck, K, Grove, F O, Dewitt, R A, Shiroff, A H, Hayes   +4 more
openaire   +2 more sources

Clinical Evaluation of the EMIT® Procainamide and N-Acetylprocainamide Assay

Therapeutic Drug Monitoring, 1979
Procainamide and its major metabolite, N-acetylprocainamide, were measured by the homogeneous enzyme immunoassay technique (EMIT). The reagents for the EMIT assays were supplied as a separate matched set for each assay. There is no cross-reactivity by procainamide in the assay for N-acetylprocainamide or by N-acetylprocainamide in the assay for ...
C B, Walberg, S H, Wan
openaire   +2 more sources

Kinetic Analysis of the Vasodilator and Ganglionic Blocking Actions of N-Acetylprocainamide

Journal of Cardiovascular Pharmacology, 1982
The hypotensive effects of N-acetylprocainamide (NAPA) were studied in anesthetized dogs and in a normal subject. In dogs, intravenous NAPA infusions reduced mean arterial pressure and the pressor response of the isolated, perfused gracilis muscle vascular bed to preganglionic, but not postganglionic, sympathetic stimulation.
J R, Eudeikis, T K, Henthorn, J J, Lertora, A J, Atkinson, G C, Chao, W, Kushner   +5 more
openaire   +2 more sources

Comparative antiarrhythmic efficacy of intravenous N-acetylprocainamide and procainamide

European Journal of Clinical Pharmacology, 1979
Ten patients with persistent ventricular arrhythmia were studied in a comparison of the antiarrhythmic efficacy of N-acetylprocainamide (NAPA) and procainamide (PA). Each patient performed three exercise tests for 40 min., on different days, with submaximal and fixed work loads. During the first exercise test no drug was administered.
C, Sonnhag, E, Karlsson
exaly   +3 more sources

Acecainide (N-Acetylprocainamide)

Drugs, 1990
Acecainide (N-acetylprocainamide), the N-acetylated metabolite of procainamide, is a Class III antiarrhythmic agent. It can be given either intravenously or orally, and is eliminated primarily by renal excretion. In a small number of noncomparative and placebo-controlled short term therapeutic trials acecainide markedly reduced premature ventricular ...
D W, Harron, R N, Brogden
openaire   +2 more sources

Pharmacokinetics of N-acetylprocainamide in patients profiled with a stable isotope method

Clinical Pharmacology and Therapeutics, 1989
N-Acetylprocainamide (NAPA) absorption and disposition were profiled in five patients with ventricular arrhythmias by the simultaneous intravenous administration of NAPA-13C and oral administration of a 500 mg NAPA hydrochloride tablet. NAPA distribution was modeled with a three compartment mammillary system.
A J, Atkinson, T I, Ruo, A A, Piergies, H C, Breiter, T J, Connelly, G S, Sedek, D, Juan, G L, Hubler, A M, Hsieh   +8 more
openaire   +2 more sources

N-Acetylprocainamide kinetics and clinical response during repeated dosing

Clinical Pharmacology and Therapeutics, 1982
Kinetics of and clinical responses to N-acetylprocainamide (NAPA) were evaluated in 10 patients with chronic ventricular arrhythmias who had not responded to usual doses of currently available antiarrhythmic drugs. Kinetic data analysis was by measured NAPA concentrations (n = 149) collected during repeated dosing. Response was evaluated with serial 24-
J H, Rodman, A, Hurst, T, Gaarder, J, Cohen, R W, Jelliffe   +4 more
openaire   +2 more sources

Procainamide, N-Acetylprocainamide, Antinuclear Antibody and Systemic Lupus Erythomatosus

Angiology, 1986
Long-term therapy with procainamide (PA) leads to the systemic lupus erythematosus syndrome (SLE) in about 30% of patients and 80% develop antinuclear antibodies. Acetylation of procainamide results in the formation of N-acetylprocainamide (NAPA) the propensity of which to induce SLE and to increase antinuclear antibodies is negligible while its ...
M M, Reidenberg, D E, Drayer
openaire   +2 more sources

Torsade de pointes associated with elevated N-acetylprocainamide levels

American Heart Journal, 1985
N-acetylprocainamide (NAPA), the major metabolite of procainamide, has been shown to have separate antiarrhythmic and side effects from procainamide.l Torsade de pointes, a type of polymorphous ventricular tachycardia characterized by “twisting” of ventricular complexes around the isoelectric line and usually associated with QT prolongation,2 has been ...
H G, Stratmann, K E, Walter, H L, Kennedy   +2 more
openaire   +2 more sources